Viking Therapeutics, Inc. (VKTX)

NASDAQ: VKTX · IEX Real-Time Price · USD
-2.06 (-2.98%)
At close: May 17, 2024, 4:00 PM
+0.47 (0.70%)
Pre-market: May 20, 2024, 4:46 AM EDT
Market Cap 7.39B
Revenue (ttm) n/a
Net Income (ttm) -93.72M
Shares Out 110.27M
EPS (ttm) -0.93
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 4,129,030
Open 69.99
Previous Close 69.06
Day's Range 66.68 - 71.09
52-Week Range 8.28 - 99.41
Beta 1.12
Analysts Strong Buy
Price Target 103.44 (+54.39%)
Earnings Date Apr 24, 2024

About VKTX

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phas... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Apr 29, 2015
Employees 27
Stock Exchange NASDAQ
Ticker Symbol VKTX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for VKTX stock is "Strong Buy." The 12-month stock price forecast is $103.44, which is an increase of 54.39% from the latest price.

Price Target
(54.39% upside)
Analyst Consensus: Strong Buy
Stock Forecasts


Amgen, newer rivals could threaten Novo Nordisk and Eli Lilly's weight loss drug dominance

Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.

12 days ago - CNBC

Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today Results From Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Demonstrated Up to 13.1% Placebo-Adjusted Weight Loss (14.7% From Baseline) a...

25 days ago - PRNewsWire

Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX

Biotech stocks are having a relatively strong year as investors focus on the growing M&A in the healthcare space. Johnson & Johnson is acquiring Shockwave Medical while Novo Nordisk is buying Catalent...

Other symbols: RXRXSANA
4 weeks ago - Invezz

Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024

Conference Call Scheduled for Wednesday, April 24 at 4:30 p.m. Eastern Time SAN DIEGO , April 17, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmace...

4 weeks ago - PRNewsWire

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.

4 weeks ago - Market Watch

This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

5 weeks ago - Market Watch

Viking Files Registration Statement with SEC for Proposed Initial Public Offering

LOS ANGELES, April 5, 2024 /PRNewswire/ -- Viking Holdings Ltd ("Viking") today announced that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commissi...

6 weeks ago - PRNewsWire

VKTX, JANX and these biotech stocks are surging in 2024

Forget artificial intelligence stocks like Nvidia and Super Micro Computer. Biotech stocks are doing much better this year.

6 weeks ago - Invezz

Healthcare stocks fade as obesity-drug optimism fades

Healthcare companies fell sharply Monday as ebullience about a new class of weight control drugs subsided.

Other symbols: NVO
6 weeks ago - Market Watch

Viking Therapeutics' positive results for oral weight-loss drug has analysts backing buy ratings

Viking Therapeutics Inc.'s stock rose 1.9% early Wednesday to add to its prior-day gains, as analysts welcomed positive data from the company's early trial of an oral weight-loss treatment — the lates...

7 weeks ago - Market Watch

Topping the tape: Viking soars on oral weight loss drug

The 'Fast Money' traders weigh in on Viking Thera stock soaring on its obesity pill data.

7 weeks ago - CNBC Television

Viking Therapeutics stock ($VKTX) pops 20% on oral weight-loss drug trial data

Viking Therapeutics Inc (NASDAQ: VKTX) is up nearly 20% on Tuesday after reporting encouraging early-stage data for its experimental weight-loss oral drug. Is Viking Therapeutics' oral weight-loss dru...

7 weeks ago - Invezz

Viking Therapeutics stock jumps 15% on promising weight loss pill data

The Viking study results add to the growing excitement around the biotech company and its potential in the budding weight loss market.

7 weeks ago - CNBC

Viking Therapeutics says its experimental tablet reduced weight in early-stage study

Viking Therapeutics said on Tuesday its experimental tablet helped reduce weight in patients in an early-stage trial and was shown to be safe and effective in the study.

7 weeks ago - Reuters

Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735

Up to 3.3% Placebo-Adjusted Mean Weight Loss (5.3% from Baseline) Observed After 28 Days VK2735 Shown to be Safe and Well-Tolerated in 28-Day Study with Low Rates of GI-Related Adverse Events Phase 2 ...

7 weeks ago - PRNewsWire

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

Contenders are beginning to emerge from the lab, some with the potential to unseat Lilly's Zepbound and Novo's Wegovy.

Other symbols: GPCRNVOPFE
2 months ago - Barrons

Viking Therapeutics faces higher bar for oral weight-loss drug after strong readout from rival

Viking Therapeutics Inc.'s stock fell 5.6% Friday, in a pullback from recent highs, after strong data from Novo Nordisk on an oral version of its weight-loss drug raised the competitive bar for Viking...

2 months ago - Market Watch

The Emergence of Strong Weight Loss Drug Players

Viking Therapeutics (VKTX) and Zealand Pharma report a successful phase 2 for weight loss drugs. Maurits Pot discusses the emergence of strong weight loss drug players.

2 months ago - Schwab Network

Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares

SAN DIEGO , March 4, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic an...

2 months ago - PRNewsWire

Three-Stock Lunch: Super Micro Computer, Deckers Outdoor, and Viking Thera

Jerry Castellini, CastleArk Management co-founder, joins 'Power Lunch' to discuss plays for three stocks, including Super Micro Computer, Deckers Outdoor, and Viking Thera.

Other symbols: DECKSMCI
2 months ago - CNBC Television

Viking Therapeutics emerges as a strong weight loss drug player — or takeover target

Some Wall Street analysts said Viking's experimental obesity treatment may be "best-in-class" following the release of midstage trial data.

2 months ago - CNBC

Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock

SAN DIEGO , Feb. 28, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic an...

2 months ago - PRNewsWire

Viking Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO, Feb. 27, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and...

2 months ago - PRNewsWire

More transparency in pharmaceuticals will be a tailwind for the space, says BMO's Evan Seigerman

Evan Seigerman, BMO biotech analyst, joins 'Power Lunch' to discuss the health care ecosystems in pharmaceuticals.

Other symbols: ABBVLLYMRKNVO
2 months ago - CNBC Television

Viking Therapeutics' stock more than doubles as investors cheer cheap entry to weight-loss-drug craze

Viking Therapeutics Inc.'s stock soared 120% Tuesday to a record high, after the company announced positive results from a Phase 2 trial of its weight-loss drug VK2735, a GLP-1 receptor agonist that i...

2 months ago - Market Watch